Physicians and regulators are concerned that changes to a patient’s genome might have unintended, life-altering consequences
It will be imperative to understand the off-target risk profile of your therapy to inform regulatory filings, support patient and clinician decision making, and to conduct post market surveillance
Invaluable gene editing off-target insights from initial research to patient therapies
Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic.
SeQure Dx comprehensively evaluates and confirms on- and off-target events using proprietary analytical tools that deliver unparalleled sensitivity and scalability.
Our diagnostics are editor-agnostic and scalable — providing both individual and population level insight.
Join the team – help us make safe gene editing a reality
Come join an energetic, focused, and dynamic team that supports career growth as well as personal well-being.
-
05.03.23 || SeQure Dx to present at American Society of Gene and Cell Therapy (ASGCT) on the importance of incorporating population heterogeneity evaluation into gene editing and cell therapy off-target analyses
-
11.16.22 || SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients
Building on Dr. J. Keith Joung’s ONE-seq platform, SeQure Dx has developed a portfolio of assays and data solutions to find, assess, and manage off-target risks from discovery to clinical development to patient impact.Full Release ❯